Marquette General Cancer Center

 

Breast

 

Study Name -NSABP PROTOCOL B-43

 

Study Description -
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive
Ductal Carcinoma In Situ Resected by Lumpectomy

 

IRB Open Date - 06-11-2008

 

Consent Pre Entry

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

Study Name - NSABP B44 Beth

 

Study Description -
NSABP B44 BETH - A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab CIRG (TRIO) 011/NSABP B44-1/B020906.

 

IRB Open Date - 04-09-2008

 

Consent- form - Her2 testing

 

Consent - NSABP B44 Beth

 

Data Privacy Statement for Research Studies

 

 

Study Name - TAILOR X

Addendum

 

Study Description -
Program for the Assessment of Clinical Cancer Tests (PACCT-1) Trial Assigning IndividuaLized Options for Treatment (TAILORx)

 

IRB Open Date - 08-08-2007

 

Consent-Form

 

Data Privacy Statement for Research Studies

 

 

Study Name - SWOG - S0307

 

Study Description -
Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.

 

IRB Open Date - 08-08-2007

 

Consent-Form

 

Data Privacy Statement for Research Studies

 

 

 

Study Name - SOFT

 

Study Description -
SOFT - Suppression of Ovarian Function Trial, A Phase III CTSU Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer.

 

IRB Open Date -10-12-2006

 

Consent-Form

 

Data Privacy Statement for Research Studies

 

 

Study Name - NSABP B-42

 

Study Description -
NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.

 

IRB Open Date - 09-13-2006

 

Consent-Form

 

 

Data Privacy Statement for Research Studies

 

 

Study Name - SWOG S0226

 

Study Description -
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer

 

IRB Open Date - 02-08-2006

 

Consent-Form

 

Data Privacy Statement for Research Studies

 

<< Back